Dataset Information

Compound hazards: An examination of how hurricane protective actions could increase transmission risk of COVID-19.

ABSTRACT: Hurricane season brings new and complex challenges as we continue to battle the COVID-19 pandemic. In May 2020, the National Oceanic and Atmospheric Administration has predicted nearly twice the normal number of tropical storms and hurricanes this season, while projections of COVID-19 models continue to rise in the United States as the Atlantic hurricane season progresses. Our research examines the critical intersection of hurricane response and public health in Harris County, Texas. We examine a hypothetical case of the 2017 Hurricane Harvey occurring amid the current pandemic. This research uses point of interest visitations as location intelligence data provided by SafeGraph together with Social Vulnerability Index and historical flood data to examine the critical intersection of natural hazard planning and response and the COVID-19 pandemic to assess the risks of a compound hazard situation. COVID-19 transmission hotspots and businesses in a community due to storm preparation activity were identified. The main drivers of transmission risk arise from overall pandemic exposure and increased interpersonal contact during hurricane preparation. Residents of health-risk areas will need to make logistical arrangements to visit alternative medical facilities for treatments related to either COVID-19 or physical impacts, such as injuries, due to the hurricane risks. Points of interest needed for disaster preparation are more likely to be situated in high-risk areas, therefore making cross-community spread more likely. Moreover, greater susceptibility could arise from social vulnerability (socioeconomic status and demographic factors) and disrupted access to healthcare facilities. Results from this study can be used to identify high-risk areas for COVID-19 transmission for prioritization in planning for temporary healthcare centers and other essential services in low-risk areas. Understanding the interplay between disaster preparation and the restrictive environment laid out by the pandemic is critical for community leaders and public health officials for ensuring the population has sufficient access to essential infrastructure services. The findings from this study can help guide the direction of disaster planning and pandemic response strategies and policies.

SUBMITTER: Dargin JS

PROVIDER: S-EPMC8443318 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Damage in COVID-19 results from both the SARS-CoV-2 virus and its triggered overactive host immune responses. Therapeutic agents that focus solely on reducing viral load or hyperinflammation fail to provide satisfying outcomes in all cases. Although viral and cellular factors have been extensively profiled to identify potential anti-COVID-19 targets, new drugs with significant efficacy remain to be developed. Here, we report the potent preclinical efficacy of ALD-R491, a vimentin-targeting small molecule compound, in treating COVID-19 through its host-directed antiviral and anti-inflammatory actions. We found that by altering the physical properties of vimentin filaments, ALD-491 affected general cellular processes as well as specific cellular functions relevant to SARS-CoV-2 infection. Specifically, ALD-R491 reduced endocytosis, endosomal trafficking, and exosomal release, thus impeding the entry and egress of the virus; increased the microcidal capacity of macrophages, thus facilitating the pathogen clearance; and enhanced the activity of regulatory T cells, therefore suppressing the overactive immune responses. In cultured cells, ALD-R491 potently inhibited the SARS-CoV-2 spike protein and human ACE2-mediated pseudoviral infection. In aged mice with ongoing, productive SARS-CoV-2 infection, ALD-R491 reduced disease symptoms as well as lung damage. In rats, ALD-R491 also reduced bleomycin-induced lung injury and fibrosis. Our results indicate a unique mechanism and significant therapeutic potential for ALD-R491 against COVID-19. We anticipate that ALD-R491, an oral, fast-acting, and non-cytotoxic agent targeting the cellular protein with multipart actions, will be convenient, safe, and broadly effective, regardless of viral mutations, for patients with early- or late-stage disease, post-COVID-19 complications, and other related diseases. IMPORTANCE With the Delta variant currently fueling a resurgence of new infections in the fully vaccinated population, developing an effective therapeutic drug is especially critical and urgent in fighting COVID-19. In contrast to the many efforts to repurpose existing drugs or address only one aspect of COVID-19, we are developing a novel agent with first-in-class mechanisms of action that address both the viral infection and the overactive immune system in the pathogenesis of the disease. Unlike virus-directed therapeutics that may lose efficacy due to viral mutations, and immunosuppressants that require ideal timing to be effective, this agent, with its unique host-directed antiviral and anti-inflammatory actions, can work against all variants of the virus, be effective during all stages of the disease, and even resolve post-disease damage and complications. Further development of the compound will provide an important tool in the fight against COVID-19 and its complications, as well as future outbreaks of new viruses.

Dataset Information

Compound hazards: An examination of how hurricane protective actions could increase transmission risk of COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets